Abstract

BackgroundHuman papillomaviruses (HPVs) are the primary etiological agents of cervical cancer and are also involved in the development of other tumours (skin, head and neck). Serological survey of the HPV infections is important to better elucidate their natural history and to disclose antigen determinants useful for vaccine development. At present, the analysis of the HPV-specific antibodies has not diagnostic value for the viral infections, and new approaches are needed to correlate the antibody response to the disease outcome. The aim of this study is to develop a novel ELISA, based on five denatured recombinant HPV16 proteins, to be used for detection HPV-specific antibodies.MethodsThe HPV16 L1, L2, E4, E6 and E7 genes were cloned in a prokaryotic expression vector and expressed as histidine-tagged proteins. These proteins, in a denatured form, were used in ELISA as coating antigens. Human sera were collected from women with abnormal PAP smear enrolled during an ongoing multicenter HPV-PathogenISS study in Italy, assessing the HPV-related pathogenetic mechanisms of progression of cervical cancer precursor lesions. Negative human sera were collected from patients affected by other infectious agents. All the HPV-positive sera were also subjected to an avidity test to assess the binding strength in the antigen-antibody complexes.ResultsMost of the sera showed a positive reactivity to the denatured HPV16 proteins: 82% of the sera from HPV16 infected women and 89% of the sera from women infected by other HPV genotypes recognised at least one of the HPV16 proteins. The percentages of samples showing reactivity to L1, L2 and E7 were similar, but only a few serum samples reacted to E6 and E4. Most sera bound the antigens with medium and high avidity index, suggesting specific antigen-antibody reactions.ConclusionThis novel ELISA, based on multiple denatured HPV16 antigens, is able to detect antibodies in women infected by HPV16 and it is not genotype-specific, as it detects antibodies also in women infected by other genital HPVs. The assay is easy to perform and has low cost, making it suitable for monitoring the natural history of HPV infections as well as for detecting pre-existing HPV antibodies in women who receive VLP-based HPV vaccination.

Highlights

  • Human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer and are involved in the development of other tumours

  • This paper reports the development of an in-house ELISA system, based on five HPV16 proteins expressed in Escherichia coli (E. coli)

  • A different immunogenicity of HPV genotypes could account for the markedly different prevalence of HPV genotypes in different geographic regions [5]. These results suggest that our multiple ELISA system, based on denatured HPV16 proteins, could be used for detection of HPV-specific antibodies in women infected by different viral genotypes, a larger number of sera needs to be analysed for its standardization

Read more

Summary

Introduction

Human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer and are involved in the development of other tumours (skin, head and neck). The aim of this study is to develop a novel ELISA, based on five denatured recombinant HPV16 proteins, to be used for detection HPV-specific antibodies. Methods: The HPV16 L1, L2, E4, E6 and E7 genes were cloned in a prokaryotic expression vector and expressed as histidinetagged proteins These proteins, in a denatured form, were used in ELISA as coating antigens. Most of the sero-epidemiological studies have focused on confirming the relationship between the presence of HPV antibodies and the detection of anogenital cancers or their precursors The majority of these studies have used either virus like particles (VLPs) or E6/E7 oncoprotein-based serological assays, while other HPV proteins have been used as antigens less frequently [2,6,7]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call